United Health Products, Inc.

United Health Products, Inc. develops and markets patented hemostatic gauze products for wound care and surgical bleeding control. The company is based in the United States and operates through its CelluSTAT product line and related branded formats, with manufacturing and packaging performed through contract and service providers.

0.03

— United Health Products, Inc.
	%
Hemostatic gauze	70% Cotton-based gauze designed to absorb drainage and help control bleeding.
Wound care dressings	20% Superficial wound and external bleeding products used in healthcare settings.
Branded surgical/wound formats	10% Product formats and trademarks associated with the company’s gauze platform.

The company’s target customers are healthcare providers that need products for bleeding control and wound management,...

Hospitals and surgery centersprimary
Buy hemostatic gauze for internal surgical bleeding control and procedural use.
Clinics and physicianssecondary
Use the products for superficial wounds, drainage absorption, and external bleeding.
Medical technology partnersprimary
May commercialize, distribute, or acquire the product platform.
Surgical device and wound care companiesprimary
Potential channel partners or strategic buyers for the product line.

The company is based in the United States, where its products are cut, packaged, and sterilized by service providers...

•United States is the core operating and manufacturing base
•Cutting, packaging, and sterilization are performed in the U.S.
•Commercial opportunity is framed around U.S. and international surgery markets
•No country-level revenue disclosure was provided in the excerpts
•Geographic exposure is tied to FDA approval and market access

The company is focused on obtaining FDA pre-market approval for its CelluSTAT hemostatic gauze so it can address...

Obtain FDA PMA for CelluSTATshort-term

Regulatory approval is the key gate to the company’s intended surgical market expansion.

Secure commercialization partnershort-term

A partner can provide distribution, market access, and execution capacity.

Maximize value through strategic transactionmedium-term

Management has indicated a sale or merger may be the preferred long-term path.

The company faces substantial regulatory risk because its core growth plan depends on FDA PMA approval, which cannot be...

critical

FDA PMA not granted

The company’s surgical market strategy depends on approval for Class III use.

Scope: CelluSTAT and the Class III surgical market
Materiality: high

critical

Going-concern and liquidity constraints

The company has not yet reached operating scale sufficient to fund overhead internally.

Scope: Corporate funding and development operations
Materiality: high

high

Dilution from equity financing

Future capital raises may be needed to fund regulatory and commercialization efforts.

Scope: Common stock issuance and convertible financing
Materiality: high

high

Commercial execution dependence on partners

The company does not intend to fully commercialize independently.

Scope: Distribution, sales, and market access
Materiality: medium

medium

Competition in hemostatic and surgical device markets

Established competitors may have stronger regulatory, sales, and hospital relationships.

Scope: Wound care and surgical hemostats
Materiality: medium

Stock-based compensation

Operating expenses and equity dilution

Going-concern assessment

Disclosure risk and financial statement presentation

Fair value of financing instruments

Liabilities, equity, and financing costs

United Health Products, Inc.

FDA PMA not granted

Going-concern and liquidity constraints

Dilution from equity financing

Commercial execution dependence on partners

Competition in hemostatic and surgical device markets

UNITED THERAPEUTICS Corp

UNITEDHEALTH GROUP INC

UNITED GUARDIAN INC

UFP TECHNOLOGIES INC

MANNKIND CORP

UNIVERSAL SAFETY PRODUCTS, INC.